FOURKITES
23.8.2022 10:18:11 CEST | Business Wire | Press release
Leading real-time supply chain visibility platform FourKites ® today announces that its carrier data will be used to enhance 3T’s global digital transport platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220823005400/en/
The deal will give 3T’s shipper customers access to FourKites’ supply chain visibility data, bringing them powerful flexibility in the way they use carriers, thereby reducing costs and improving sustainability initiatives.
“FourKites’ broad coverage of carriers in Europe allows us to give our customers a more comprehensive shipment visibility offering as part of our digital transport management software,” says Rob Hutton, Group Sales and Marketing Director at 3T. “That gives them more flexibility in the carriers they can work with, keeping both costs and carbon emissions down.”
3T is a UK-based global SaaS digital transport platform provider, whose transport management solutions dovetail neatly with FourKites’ supply chain visibility offering. 3T’s pioneering cloud-based platform provides a seamless shipper/carrier ecosystem with functionality including transport assignment, rate management and tendering, as well as automatic carrier allocation. It also facilitates supply chain collaboration by enabling AI-driven dynamic planning and execution across multiple accounts, harnessing real-time data to reduce empty running of vehicles.
FourKites is the market leader in real-time, end-to-end supply chain visibility, extending visibility beyond transportation into yards, warehouses, stores and more. The companies’ combined offering signals a paradigm shift in 3T’s ability to not only know the status and position of every shipment, but to also dynamically react to changes from plan.
“Giving 3T customers access to FourKites data will allow them to make better decisions, optimising the way they use carriers,” says Marc Boileau, Senior VP of Sales and Carrier Operations at FourKites Europe. “That has cost benefits for them, it improves their service to customers with almost no administrative work required, and it gives them the most accurate estimated times of arrival available in the market today. We are thrilled to be working together with the 3T team to better support their customer base.”
Carbon reductions
3T already gives customers multiple options to capture carrier data. However, with the addition of FourKites’ real-time supply chain data, 3T customers will now have all the data necessary to complete their operational visibility picture and ultimately help them reduce both carbon emissions and costs through improved resource utilisation.
“We see a huge efficiency opportunity for both shippers and carriers by using data to identify and reduce empty running across the industry. This will be essential to meet our collective environmental targets,” says Rob, "and it’s why this partnership is so exciting for us.”
This is just one aspect of the improved planning shippers can achieve with the 3T-FourKites partnership.
“You’re likely to get a good price by placing a shipment on an empty running truck,” says Marc, “so costs go down. But carriers have fewer empty runs, too, so they see driver productivity improve. It’s win-win. The better your visibility, the better you can plan to optimise your transport.”
In March, FourKites announced its Sustainability Hub, which offers granular emissions tracking, industry benchmarks, analytics and scenario modeling to help customers meet sustainability goals. In addition, the company offers Dynamic Yard ® , a new category of software that connects traditional, siloed yard management software with FourKites’ real-time supply chain data and predictive ETAs to provide insight into driver detention patterns, labor efficiency and more to reduce dwell and inform carbon reduction strategies. Last year, customers who used Dynamic Yard emitted 20% fewer carbon emissions than non-Dynamic Yard users through reductions in truck idle times.
Notes for editors
About FourKites®
Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2.5 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching more than 200 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,100 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit www.fourkites.com .
About 3T
3T Logistics and Technology Group is an award-winning UK head-quartered SaaS transport management technology business with clients including JCB, Klockner Pentaplast and Kraft Heinz. Founded in 2000 as a 4th Party Logistics Provider (4PL), 3T has evolved to become a globally recognised transportation management (TMS) technology provider. The company’s vision and mission remain the same since its inception, to improve service, reduce cost to shippers and carriers and remove empty running through collaboration and the smart use of technology.
To learn more about 3T please visit their website: https://www.3t-ltg.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005400/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
